已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Long-term effects of azithromycin mass administration to reduce childhood mortality on Streptococcus pneumoniae antimicrobial resistance: a population-based, cross-sectional, follow-up carriage survey

阿奇霉素 马车 肺炎链球菌 医学 抗菌剂 人口 抗生素耐药性 横断面研究 微生物学 生物 抗生素 环境卫生 病理
作者
Akuzike Kalizang’oma,Jia Mun Chan,Khumbo Kalua,Farouck Bonomali,Comfort Brown,Jacquline Msefula,David Chaima,Lyson Samikwa,Harry Meleke,John Hart,Alison Craik,Chrispin Chaguza,Rory J. Cave,Jennifer Cornick,Brenda Kwambana-Adams,Stephen D. Bentley,Thandie S. Mwalukomo,Dorothee van Breevoort,Robin L. Bailey,Ana Belén Ibarz-Pavón
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:25 (10): 1116-1127 被引量:15
标识
DOI:10.1016/s1473-3099(25)00212-9
摘要

BACKGROUND: Mass drug administration (MDA) programmes with the macrolide antibiotic azithromycin to reduce childhood mortality are expanding in Africa; however, concerns remain about the long-term effects of these programmes on antimicrobial resistance (AMR). We aimed to evaluate the persistence and spread of Streptococcus pneumoniae AMR following a community-randomised MDA trial. METHODS: This population-based, cross-sectional, pneumococcal carriage survey was conducted in Mangochi, Malawi, 3·5 years after the MORDOR trial, in which communities received twice-yearly azithromycin or placebo for 2 years. Eligible participants in this carriage survey were children aged 4-9 years who lived in an azithromycin-treated or placebo-treated cluster during the MORDOR trial, and children aged 1-3 years who were resident in a cluster but born after the MORDOR trial ended. Nasopharyngeal swabs were collected from participants and analysed by whole genome sequencing; pneumococcal genomes obtained from a distant site in Malawi, in which MDA had not been conducted, were used as reference genomes. The primary outcome was the prevalence of S pneumoniae macrolide resistance, comparing placebo-treated and azithromycin-treated clusters at baseline, 6 months post-MDA, and 3·5 years post-MDA. FINDINGS: Between April 8 and May 14, 2021, 924 children aged 1-9 years were screened, of whom 19 were excluded and 905 were recruited to the follow-up carriage survey: 452 from azithromycin-treated clusters and 453 from placebo-treated clusters of the MORDOR trial. We assessed 426 isolates from these participants (190 from azithromycin-treated clusters and 236 from placebo-treated clusters), as well as samples from the baseline of the MORDOR trial (164 isolates; 83 from azithromycin-treated clusters and 81 from placebo-treated clusters) and from 6 months post-MDA (223 isolates; 119 from azithromycin-treated clusters and 104 from placebo-treated clusters). In azithromycin-treated clusters, macrolide resistance increased from 21·7% (95% CI 14·2-31·7; 18 of 83 isolates) at baseline to 31·9% (24·2-40·8; 38 of 119 isolates) 6 months post-MDA and to 32·1% (25·9-39·0; 61 of 190 isolates) 3·5 years post-MDA. In placebo-treated clusters, resistance increased from 21·0% (13·5-31·1; 17 of 81 isolates) at baseline to 25·0% (17·7-34·1; 26 of 104 isolates) 6 months post-MDA and to 30·9% (25·4-37·1; 73 of 236 isolates) 3·5 years post-MDA. No significant differences were observed in odds ratios between treatment groups across the survey timepoints: 0·97 (95% CI 0·36-2·55) at baseline, 1·46 (0·67-3·17) at 6 months post-MDA, and 1·12 (0·66-1·91) at 3·5 years post-MDA. Macrolide resistance in the non-MDA site remained stable: 16·9% (95% CI 12·8-21·8; 45 of 267 isolates) at baseline, 16·5% (13·3-20·3; 70 of 424 isolates) at 6 months, and 16·5% (12·5-21·4; 44 of 267 isolates) at 2·5 years. Among children born into azithromycin-treated clusters after MDA, macrolide resistance was 36·0% (27·7-45·1; 41 of 114 children). Multidrug resistance to at least three antibiotic classes was significantly higher in azithromycin-treated (p=0·0015) and placebo-treated (p<0·0001) clusters than in the comparator population at 3·5 years post-MDA and was associated with integrative conjugative elements. INTERPRETATION: Azithromycin MDA is associated with macrolide resistance that persists and potentially spreads to untreated populations. The co-existence of multidrug resistance and transmissible resistance on integrative conjugative elements in these populations is a public health concern. Careful monitoring of AMR is essential in areas where MDA is implemented. FUNDING: The Gates Foundation, the National Institute for Health and Care Research, and the Wellcome Trust.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
milk完成签到 ,获得积分10
2秒前
传奇3的应助被数智采纳,获得10
3秒前
Danny完成签到,获得积分10
3秒前
3秒前
5秒前
lujibaqi发布了新的文献求助10
5秒前
忘忧草完成签到 ,获得积分10
5秒前
Anserbe完成签到 ,获得积分10
5秒前
6秒前
It完成签到 ,获得积分10
6秒前
GingerF的应助被DW采纳,获得50
6秒前
sss完成签到,获得积分20
10秒前
10秒前
夏目完成签到,获得积分10
11秒前
谦让夏山完成签到 ,获得积分10
11秒前
土豆豆完成签到 ,获得积分10
12秒前
兴奋枫完成签到,获得积分10
12秒前
gmy发布了新的文献求助10
12秒前
小正完成签到,获得积分10
13秒前
yueqi完成签到,获得积分10
14秒前
一口一完成签到 ,获得积分10
15秒前
yingying完成签到 ,获得积分10
16秒前
WYT发布了新的文献求助10
16秒前
Agiff完成签到 ,获得积分10
17秒前
友好巧曼完成签到,获得积分10
18秒前
dzy完成签到,获得积分10
19秒前
Yyusx完成签到 ,获得积分10
19秒前
巴音布鲁克完成签到 ,获得积分10
20秒前
科研通AI6.3的应助被xx采纳,获得10
22秒前
gmy完成签到,获得积分10
22秒前
翠花完成签到,获得积分10
24秒前
乐乐笑语的应助被友好巧曼采纳,获得10
24秒前
呱唧完成签到 ,获得积分10
26秒前
吞吞完成签到 ,获得积分10
27秒前
沉默土豆完成签到 ,获得积分10
29秒前
31秒前
32秒前
好好好完成签到 ,获得积分10
33秒前
33秒前
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184828
求助须知:如何正确求助?哪些是违规求助? 9573791
关于积分的说明 21833034
捐赠科研通 7782127
什么是DOI,文献DOI怎么找? 3434405
关于科研通互助平台的介绍 2558545
邀请新用户注册赠送积分活动 2481067